연구동향 분석

Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial

임호영 최원일 김성현 남승현 김경하 문영철 오도연 황헌규 이근욱 송은기 권용식 방수미 2019년

논문상세정보
인용/피인용
' Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • neoplasms
  • recur-rence
  • rivaroxaban
  • therapeutics
  • venous thromboembolism
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
956 0

0.0%

' Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial' 의 참고문헌

  • Venous thromboembolism prophylaxis and treatment in patients with cancer : American Society of Clinical Oncology clinical practice guideline update
    Lyman GH [2013]
  • Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer
    Schulman S [2015]
  • Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months : the DALTECAN Study
    Francis CW [2015]
  • Treatment of cancer-associated thrombosis
    Lee AY [2013]
  • Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer : a randomized clinical trial
    Lee AYY [2015]
  • Thrombosis and cancer
    Young A [2012]
  • The incidence, risk factors, and prognosis of recurrent venous thromboembolism(VTE)in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE
    Yhim HY [2013]
  • The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer
    Lee KW [2010]
  • The impact of bleeding complications in patients receiving target-specific oral anticoagulants : a systematic review and meta-analysis
  • Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism : a comparison with symptomatic patients
  • Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients : a pooled analysis of 926 patients
  • Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer(EINSTEIN-DVT and EINSTEIN-PE) : a pooled subgroup analysis of two randomized controlled trials
    Prins MH [2014]
  • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
  • Oral rivaroxaban for symptomatic venous thromboembolism
  • Oral apixaban for the treatment of venous thromboembolism in cancer patients : results from the AMPLIFY trial
    Agnelli G [2015]
  • Oral apixaban for the treatment of acute venous thromboembolism
    Agnelli G [2013]
  • Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism
  • Management of venous thromboembolism:an update
    Piran S [2016]
  • Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
    Mandala M [2011]
  • Management of bleeding complications in patients with cancer on DOACs
    Schulman S [2016]
  • Management of anticoagulation before and after elective surgery
    Kearon C [1997]
  • Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    Lee AY [2003]
  • International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
    Farge D [2016]
  • Incidence of venous thromboembolism in Korea : from the Health Insurance Review and Assessment Service database
    Jang MJ [2011]
  • Incidence of venous thromboembolism following major surgery in Korea : from the Health Insurance Review and Assessment Service database
    Yhim HY [2014]
  • Gastrointestinal bleeding with the new oral anticoagulants : defining the issues and the management strategies
    Desai J [2013]
  • Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
    Ay C [2015]
  • Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
  • Edoxaban for venous thromboembolism in patients with cancer : results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
    Raskob GE [2016]
  • Edoxaban for the treatment of cancer-associated venous thromboembolism
    Raskob GE [2018]
  • Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
    임호영 [2014]
  • Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism
    Louzada ML [2012]
  • Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    Schulman S [2005]
  • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Schulman S [2009]
  • Antithrombotic therapy for VTE disease : CHEST guideline and expert panel report
    Kearon C [2016]